Browse the evidence

Primary Obesity Surgery Endoluminal (POSE) 2.0 and Endomina Gastric Plication are effective endoscopic gastric remodeling techniques that produce significant weight loss and metabolic improvements, though with varying efficacy profiles compared to ESG.

POSE 2.0 and Endomina are endoscopic options that use full-thickness plications to reduce stomach size. They are effective for weight loss and metabolic improvement, though ESG may offer higher weight loss percentages in some studies. They are suitable for patients seeking minimally invasive alternatives to surgery.

Personalized behavioral weight loss (PBWL) involving a 4-week experimentation phase with continuous glucose monitoring (CGM) yields significantly greater 12-week weight loss than standard behavioral weight loss (BWL) with fixed prescriptions.

Instead of sticking to one diet, try a 4-week 'experiment' phase. Use a continuous glucose monitor (CGM) to test different macronutrient ratios (low-carb vs. low-fat) and meal frequencies (3 meals vs. snacks). Track how your blood sugar and hunger respond to each. After 4 weeks, pick the combination that gave you the best glucose control and felt most sustainable, then stick with it for the next 8 weeks. This personalized approach led to nearly double the weight loss of standard dieting in this study.

Higher consumption of ultraprocessed foods (UPFs) is positively associated with the prevalence of overall arthritis and specifically rheumatoid arthritis (RA) in U.S. adults, but not osteoarthritis (OA).

If you have arthritis or are at risk, reducing your intake of ultraprocessed foods (like sugary drinks, packaged snacks, and fast food) may help lower your risk of developing rheumatoid arthritis. This is because UPFs often drive inflammation and weight gain. You don't need to eliminate them entirely, but shifting your diet towards less processed options can have a measurable benefit.

Integrative Korean Medicine Treatment (IKMT), comprising personalized herbal medicine (including Ephedrae Herba) and dietitian-led lifestyle modification, produces statistically significant weight loss and blood pressure reductions in obese adults with a safety profile comparable to or better than GLP-1 receptor agonists.

This study suggests that a structured program combining personalized herbal medicine (specifically containing Ephedrae Herba) with professional dietary coaching can lead to significant weight loss (average ~8.7%, up to ~28% in best responders) and improved blood pressure. It serves as a viable alternative for individuals who cannot tolerate or afford GLP-1 medications, provided they undergo proper medical screening for contraindications like heart or liver disease.

GLP-1 receptor agonists used for weight management are associated with nutritional deficiencies, specifically protein deficiency and metabolic acidosis, which may lead to malnutrition.

When using GLP-1 medications for weight loss, pay attention to your nutrition. Reports suggest a higher risk of protein deficiency and metabolic acidosis. Ensure you are eating enough protein and staying hydrated. If you feel unwell, dizzy, or experience unusual symptoms, talk to your doctor about your diet and medication.

Higher adherence to sports nutrition guidelines, measured by the Athlete Diet Index (ADI), is associated with lower fat mass in professional athletes.

For professional athletes, eating according to sports nutrition guidelines (high ADI score) is linked to having the lowest body fat. For non-professionals, this link is weaker. If you are serious about body composition, aligning your diet with established sports nutrition standards is a key lever, especially if you have access to professional guidance.

Dietary interventions that modulate gut microbiota composition (specifically increasing SCFA-producing bacteria and reducing dysbiosis) improve metabolic health outcomes including insulin sensitivity and glucose tolerance.

To improve your metabolic health, focus on dietary patterns that support a diverse gut microbiome. This means consuming a variety of plant fibers (prebiotics) to encourage the growth of beneficial bacteria that produce short-chain fatty acids (SCFAs). These SCFAs help regulate blood sugar and insulin sensitivity. Avoid highly processed foods that can cause dysbiosis (microbial imbalance) and inflammation.

High-fat diets induce gut barrier defects and metabolic endotoxemia (elevated LPS), which triggers low-grade inflammation and compromises insulin sensitivity.

Reducing chronic high-fat intake can help maintain gut barrier integrity, preventing the leakage of inflammatory bacterial components (LPS) into the bloodstream, which may improve insulin sensitivity.

High-volume static stretching (≥15 minutes per muscle group, >3 times per week) induces muscle hypertrophy and strength increases comparable to resistance training, primarily by generating high-magnitude mechanical tension that activates mTOR/p70S6K signaling pathways.

If you cannot lift weights due to injury, age, or lack of equipment, perform static stretches for at least 15 minutes per muscle group, 3 or more times a week. Push to the point of discomfort (but not sharp pain). This can build muscle and strength similarly to weightlifting, though it takes longer per session. It is particularly useful for immobilized patients or as a supplement to your regular workouts.

Training with 4-6 or 1-3 repetitions in reserve (RIR) yields comparable strength gains, whereas training to momentary failure (0 RIR) or near-failure (0-3 RIR) results in slightly inferior strength outcomes in trained men.

For strength gains, you do not need to train to failure. Stopping sets with 1-3 reps left in the tank (RIR) produces similar or better strength results than going to failure. Training to failure may actually hinder strength progress due to excessive fatigue and reduced recovery capacity. Focus on maintaining bar speed and consistency rather than absolute exhaustion.

Higher body mass index (BMI) is associated with lower self-reported physical functioning and overall health-related quality of life (HRQoL) in people with overweight or obesity.

If you have overweight or obesity, you are statistically more likely to experience reduced physical functioning and lower quality of life as your BMI increases. This is not just about appearance; it affects your daily physical capacity and general health perception. Addressing weight and associated comorbidities is a key lever for improving these functional outcomes.

The presence of cardiovascular (CV) or metabolic comorbidities significantly reduces health-related quality of life (HRQoL) and work productivity in people with overweight or obesity, independent of BMI alone.

Having overweight or obesity is not the only factor affecting your health and work. If you have cardiovascular or metabolic conditions (like diabetes or high blood pressure), these significantly impact your quality of life and productivity. Treating these comorbidities alongside weight management is crucial for improving your daily well-being.

People with overweight or obesity experience significant work productivity impairment, particularly in terms of presenteeism and activity impairment, when they have metabolic comorbidities.

If you have overweight or obesity and metabolic conditions like diabetes, you may experience reduced work effectiveness (presenteeism) and activity limitation. This is a measurable impact of your health conditions. Managing these conditions can help improve your work productivity and overall well-being.

Triple receptor agonists (GLP-1/GIP/Glucagon) such as retatrutide achieve superior weight loss (20-24%) compared to single or dual agonists by synergistically combining satiety, nutrient partitioning, and increased energy expenditure.

If you are struggling with current GLP-1 therapies or need more aggressive weight loss, triple-agonist medications like retatrutide are the next step. They work by hitting three metabolic targets at once, leading to much higher weight loss (up to 24%) than standard drugs. This is currently an injectable treatment, but oral alternatives are being developed.

Combining amylin analogs (e.g., cagrilintide) with GLP-1 agonists (e.g., semaglutide) achieves weight loss (20-22%) through distinct neuroendocrine circuits, offering a tolerability advantage over single agents.

If you are not getting enough weight loss or side effects from GLP-1s alone, adding an amylin analog (like cagrilintide) to your regimen might help. This combination works through a different mechanism in your brain and gut, leading to significant weight loss (around 20%) and potentially better tolerability.

In integrated primary care weight management, achieving clinically meaningful weight loss (≥5% initial body weight) is significantly associated with higher treatment visit frequency and the simultaneous prescription of two or more anti-obesity medications (AOMs).

To maximize your chances of losing at least 5% of your body weight, commit to attending your scheduled monthly appointments for the first six months and discuss with your doctor the potential benefit of using two anti-obesity medications simultaneously if one isn't working. Consistent engagement and combination therapy were key factors in successful weight loss trajectories in this study.

Systematic screening for heart failure with preserved ejection fraction (HFpEF) in asymptomatic or mildly symptomatic individuals with obesity is clinically indicated to enable early detection and intervention, as obesity-related HFpEF presents with distinct pathophysiology and earlier onset.

If you have obesity, do not assume shortness of breath or fatigue is 'just part of being overweight.' Ask your doctor about screening for heart failure with preserved ejection fraction (HFpEF), especially if you have other risk factors like high blood pressure or atrial fibrillation. Early detection through specific tests (like echocardiograms or biomarker adjustments) can allow for treatments that prevent heart failure from developing.

Caffeine supplementation, while beneficial for endurance performance, may impair shooting accuracy in biathletes and should be used with caution.

Be cautious with caffeine. While it helps you ski faster, it might make your shooting less accurate. Test it in training to see how it affects your specific shooting performance before using it in competition.

Training the medial gastrocnemius with initial partial repetitions (lengthened position) produces greater hypertrophy than training with past-failure partials (full ROM followed by lengthened partials), although the evidence is currently anecdotal.

If you want to maximize calf growth, prioritize initial partials (stretching the calf at the bottom of the movement) over past-failure partials. Perform full-range calf raises to failure, then immediately drop the heel to stretch the calf and perform partial reps. However, ensure you are eating enough protein (1.6g/kg) and training consistently twice a week. The difference between strategies is small, so consistency with full-range or initial partials is more important than perfect technique.

Semaglutide improves patient-reported pain and function in chronic plantar heel pain, with approximately half of the benefit mediated by weight loss.

If you have chronic heel pain and are overweight or have Type 2 Diabetes, ask your doctor if GLP-1 medications like semaglutide might help. The study suggests these drugs can reduce pain and improve foot function, largely by helping you lose weight, which reduces stress on your feet. This is not a standard treatment yet, so discuss the risks and benefits with your provider.

Using GLP-1 RAs post-bariatric surgery can enhance weight loss outcomes and prevent weight regain, whereas using them pre-surgery (neoadjuvant) does not improve surgical outcomes and may slightly reduce weight loss.

If you have had bariatric surgery and are experiencing weight regain, adding a GLP-1 RA can help you lose additional weight. However, taking GLP-1 RAs *before* surgery does not improve surgical results and might slightly reduce the amount of weight lost from the surgery itself.

Metabolic and bariatric surgery (MBS) provides significantly greater reduction in major adverse cardiovascular events (MACE) and all-cause mortality compared to GLP-1 receptor agonist (GLP-1 RA) therapy in patients with obesity and type 2 diabetes.

If you have obesity and type 2 diabetes, metabolic surgery (like gastric bypass or sleeve gastrectomy) is currently shown to be more effective than GLP-1 medications (like semaglutide or liraglutide) at preventing heart attacks, strokes, and death. While GLP-1 drugs are important for those who cannot have surgery, surgery offers greater long-term cardiovascular protection and more sustained weight loss, though it carries surgical risks and requires lifelong nutritional monitoring.

Microbiome-targeted interventions like prebiotics, probiotics, and synbiotics show potential antihypertensive effects, but results are heterogeneous and require larger randomized trials.

While probiotics and prebiotics show promise, they are not yet a proven standalone treatment for hypertension. Focus on a healthy diet and lifestyle first, and consider these supplements as potential adjuncts under medical guidance.

Combining different weight-lowering drugs with complementary mechanisms (e.g., GLP-1 RA with activin receptor antagonist) can enhance weight loss and preserve lean body mass, potentially offering superior cardiovascular protection compared to monotherapy.

For some patients, taking a single weight-loss drug might lead to muscle loss, which isn't ideal for heart health. New combination therapies, such as pairing a GLP-1 drug with a muscle-preserving agent, are being developed to prevent this. These combinations can lead to greater fat loss and better preservation of muscle mass, which is crucial for metabolic health. While these are still emerging, they represent a promising approach for those who struggle with muscle loss on standard treatments.